Key facts
- This page summarizes Gregory H. Bailey's Form 4 filing for Serina Therapeutics, Inc. (SER).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 10 Apr 2025, 16:02.
Gregory H. Bailey - 08 Apr 2025 Form 4 Insider Report for Serina Therapeutics, Inc. (SER)
- Reporting relationship
- Director
- Issuer ticker
- SER
- Reported as of
- 08 Apr 2025
- Net transaction value
- +$3,949,999
- SEC form
- 4
- Accepted by SEC
- 10 Apr 2025, 16:02:46 UTC
- Prior SEC filing
- 19 Dec 2024
- Next SEC filing
- 07 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gregory Bailey
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gregory H. Bailey filed Form 4 for Serina Therapeutics, Inc. (SER) on 10 Apr 2025.
Change
- Previous filing in this sequence was filed on 19 Dec 2024.
- Current net transaction value: +$3,949,999.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SER
transaction
Derivative
Series A Convertible Preferred Stock
Award
- Transaction value
- $3,949,999
- Shares
- +762,548
- Change %
- Price
- $5.18
- Shares after
- 762,548
- Date
- 08 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock, $0.0001 par value
- Underlying amount
- 762,548
- Exercise price
- $5.18
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date.